$Psyence Biomedical (PBM.US)$
But other than having new major investments, a reverse split, or significant new test reports to convince Nasqao to lift (with additional extend fees), I can't think of anything else.
Unless it's bad news hahaha
But other than having new major investments, a reverse split, or significant new test reports to convince Nasqao to lift (with additional extend fees), I can't think of anything else.
Unless it's bad news hahaha
Translated
3
$Psyence Biomedical (PBM.US)$ So just like i say pbm need to settle the delisting issue.
Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq | PBM Stock News
If settle we fly but if no pbm byebye.
So why all no accept what i say😂
Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq | PBM Stock News
If settle we fly but if no pbm byebye.
So why all no accept what i say😂
16
被祝福的账户
liked and commented on
$Psyence Biomedical (PBM.US)$ Just wait for the solution for this first. Bla bla bla good news all like rainbow can see but can't touch. If today or Monday have solution for this and will be go back normal. Additionally, the presentation also next Monday until Wednesday and let us see what action or good news will come out.
If delisting settled and good news come out in presentation and have new institutions, then we will be rocket
If delisting settled and good news come out in presentation and have new institutions, then we will be rocket
4
25
被祝福的账户
liked
$Psyence Biomedical (PBM.US)$
Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant
Psyence Biomedical (Nasdaq: PBM) has entered into a conditional binding term sheet to acquire Clairvoyant Therapeutics Inc, a Canadian clinical-stage developer of psilocybin-based therapeutics. The acquisition involves issuing US$500,000in PBM common shares upon closing, with potential additional payments of up to US$500,000 ...
Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant
Psyence Biomedical (Nasdaq: PBM) has entered into a conditional binding term sheet to acquire Clairvoyant Therapeutics Inc, a Canadian clinical-stage developer of psilocybin-based therapeutics. The acquisition involves issuing US$500,000in PBM common shares upon closing, with potential additional payments of up to US$500,000 ...
3
被祝福的账户
commented on
1
被祝福的账户
commented on